ACCOLATE IS FIRST APPROVED LEUKOTRIENE ANTAGONIST, FIRST ZENECA ASTHMA AGENT; ZAFIRLUKAST HAS BROAD INDICATION: SEVERE ASTHMA ROLE NOT "FULLY CHARACTERIZED"
• By The Pink Sheet
Zeneca is undertaking to build a new therapeutic franchise in the pulmonary-asthma field with Accolate, the first leukotriene receptor antagonist to be approved by FDA. Zafirlukast cleared the agency on Sept. 26 for use in the prevention and chronic treatment of asthma in patients 12 years of age or older.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
The Trump Administration’s rhetoric and policy approaches illustrate the confusion that often arises between efforts to cut drug prices and cutting spending.